Table 1.
ARV-induced lipid changes.
| TGL | LDL-C | HDL-C | |
|---|---|---|---|
| PIs | |||
| ATV/r [135] | ↑ | ↑ | ↑/↔ |
| DRV/r [100, 136] | ↑ | ↑ | ↑/↔ |
| LPV/r [137] | ↑↑ | ↑ | ↓ |
| FPV/r [138] | ↑↑ | ↑ | ↓ |
| TPV/r [138] | ↑↑ | ↑ | ↓ |
| NRTIs | |||
| ABC [139] | ↑ | ↑ | ↑/↔ |
| FTC [138] | ↑ | ↑ | ↓ |
| 3TC [138] | ↑ | ↑ | ↓ |
| d4T [138] | ↑↑ | ↑ | ↓ |
| TDF [49, 140] | ↓ | ↓ | ↑ |
| NNRTIs | |||
| EFV [86, 141] | ↑↑ | ↑ | ↑↑ |
| NVP [138] | ↑ | ↑ | ↑↑ |
| RPV [142] | ↓ | ↑ | ↑ |
| INSTIs | |||
| RAL [143, 144] | ↔ | ↓/↔ | ↓/↔ |
| DTG [145] | ↔ | ↓/↔ | ↓/↔ |
| EVG/c [57] | ↑↑ | ↑↑ | ↓ |
| Entry Inhibitors | |||
| ENF [139] | ↓/↔ | ↓/↔ | ↑/↔ |
| MVC [146] | ↔ | ↔ | ↑/↔ |
The arrows in the above table specify the degree of change: ↑↑, moderate to large increase; ↑, small to moderate increase; ↔, no change; ↓, small to moderate decrease. ATV/r atazanavir/ritonavir, DRV/r darunavir/ritonavir, LPV/r lopinavir/ritonavir, FPV/r fosamprenavir/ritonavir, TPV/r tipranavir/ritonavir, ABC abacavir, FTC emtricitabine, 3TC lamivudine, d4T stavudine, TDF tenofovir, EFV efavirenz, NVP nevirapine, RPV rilpivirine, RAL raltegravir, DTG dolutegravir, EVG/c elvitegravir/cobicistat, ENF enfuvirtide, MVC maraviroc.